Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
about
Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinomaGemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.First- and second-line therapy for metastatic urothelial carcinoma of the bladderLocalized and locally advanced bladder cancer.Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimenState-of-the-art management of metastatic disease at initial presentation or recurrence.Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.Systemic therapy for metastatic urothelial carcinoma.Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.Management of bladder cancer: current and emerging strategies.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Emerging drugs for urothelial carcinoma.Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.Improving Systemic Chemotherapy for Bladder Cancer.Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).Vitamin E succinate induced apoptosis and enhanced chemosensitivity to paclitaxel in human bladder cancer cells in vitro and in vivo.Vinflunine in the treatment of bladder cancer.Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy.Atezolizumab in urothelial bladder carcinoma.Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
P2860
Q28344992-5C5EBB5C-AEAF-4180-91A6-DE43C2D9310AQ33364779-3C685A70-903B-4B05-87BB-497458F708A9Q33369889-A2D0279D-EBB8-419D-9598-0A8348DBB882Q33382500-9C41A8C4-6F00-414B-BC5E-CBCA1BB8CBE9Q33403679-35408F00-8120-43A4-8714-07B271349020Q33431220-18005734-A5B6-4181-8425-78F9EE5F18C3Q33923405-336242FD-C569-468F-901F-A6FF6FF0B90DQ34541463-218FBB51-8EB4-47A8-B660-3424B163D632Q34795750-15DF3317-D39B-48CF-B6EB-559E23CDCE0FQ36192053-FC00685A-CA8C-4A5F-90B8-3479DC1ECCDBQ36614243-1EA5BCB0-0EFC-4526-8852-1BC1AB0787DCQ36619428-3E9606B2-3874-403C-9E5D-7981DA0BDCD3Q36953789-870CDE64-5169-4E1F-B02D-39462DF02028Q37028356-76FC0F39-2D15-47C9-BE2E-6168D2FAB3BBQ37284023-ABAEC298-10FD-48B3-B521-0E166F6955C8Q37523855-89855EC0-7203-49DB-A69F-CE30FEE2D395Q38155201-91644A72-024D-4B4F-90FC-82FB28172CF7Q38160271-EC011109-0120-4B9B-941F-0C2F106007F1Q38612831-0EE39092-541F-45C6-A8CD-464C56997F24Q38612965-50A25F32-F411-4BB7-94CA-3B531A0F5174Q38777610-328BA765-AD52-460F-B7BA-C37CF4C0E520Q38798645-7913616D-03D4-434C-9559-4A37609C3741Q39788042-E25F8A54-6DDD-43B6-8602-D2C2A8DA5B6BQ42183149-F4F4C6E3-A7EB-4D20-986B-1891B90F48FFQ43654255-D3539577-F974-433A-92F7-7974EBB67B36Q44373064-8534D777-78EB-4E17-AC1D-4740237FD1ABQ46033801-2555D988-317C-4633-9A56-E6BDAB13E631Q47102176-079AC7A9-6DDE-473F-98E8-E1772147DE94Q47841004-E774A7AD-9EE3-4FF8-8183-A94BEFC13E53Q49081390-2B53C578-78A3-4BF1-9DD7-928919E7BB93Q53401747-78F2C225-1125-4A4B-B5E0-00F0A4332F06Q57073426-D97DA53F-41B7-4A5A-840D-C5F8C1662D67
P2860
Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Phase II study of paclitaxel i ...... cer of the bladder and ureter.
@ast
Phase II study of paclitaxel i ...... cer of the bladder and ureter.
@en
type
label
Phase II study of paclitaxel i ...... cer of the bladder and ureter.
@ast
Phase II study of paclitaxel i ...... cer of the bladder and ureter.
@en
prefLabel
Phase II study of paclitaxel i ...... cer of the bladder and ureter.
@ast
Phase II study of paclitaxel i ...... cer of the bladder and ureter.
@en
P2093
P2860
P356
P1476
Phase II study of paclitaxel i ...... cer of the bladder and ureter.
@en
P2093
Gallagher CJ
Johnson PW
Papamichael D
P2860
P2888
P304
P356
10.1038/BJC.1997.106
P407
P577
1997-01-01T00:00:00Z
P5875
P6179
1006224843